Interessenkonflikte

Leitlinien zu Diabetes und Cholesterin: 52% der Autoren mit Interessenkonflikten

2011-10-13T20:02:00.000+02:00

Neuman J, Korenstein D, Ross JS, Keyhani S. Prevalence of financial conflicts of interest among panel members producing clinical practice guidelines in Canada and United States: cross sectional study. BMJ 2011;343.Volltext Link
Beitrag im Forum Gesundheitspolitik Link

PLoS Medicine. Beiträge zu Ghost Writing, Aug. 2011

2011-09-03T15:50:00.002+02:00

Gegen ghost writing. Die Herkunft von Studien offen legen - schwierig aber notwendig
in Forum Gesundheitspolitik

Being the Ghost in the Machine: A Medical Ghostwriter's Personal View

2011-08-10T19:11:00.001+02:00

PLoS 9.8.2011

Link

Introduction
Ethical concerns about medical ghostwriting have been directed primarily at “guest” authors and the pharmaceutical companies that pay them. One voice that is largely missing is that of the ghostwriters themselves who, after all, create the documents that are in the ethical and legal crosshairs. Without them, one could argue, there can be no fraud, because it is they who create the fraudulent product.

For almost 11 years, I worked as a medical writer, creating a variety of pieces including the occasional ghostwritten article. For the most part, I never saw the finished paper, nor did I care to. This article describes what I did, why I did it, why I stopped doing it, and what I think might be done about the problem of fraud in authorship.

How Industry Uses the ICMJE Guidelines to Manipulate Authorship—And How They Should Be Revised

2011-08-10T19:05:00.002+02:00

PLoS 9. August 2011

Link

Summary Points
Academic authorship boosts the credibility of industry publications and masks their commercial function.
Alongside traditional “guest authorship” and ghostwriting, industry may simply exaggerate the contribution of named academic authors and downplay that of commercial writers, who are excluded from authorship but listed as contributors in the small print.
Rather than obstructing industry, the current International Committee of Medical Journal Editors (ICMJE) authorship guidelines provide a ready tool for misattributing authorship. Industry also relies on selective interpretations of key authorship concepts.
The ICMJE guidelines should be fundamentally revised and the concept of origination given comparable importance to authorship and contributorship.
Companies and writers who work on industry publications should be listed as byline authors.

Pillentrick des Pharmalobbyismus. Wie man Patienten um den Finger wickelt

2011-05-16T20:34:00.000+02:00

Financial Times Deutschland 14.5.2011
Link

Cardiac Society Draws Bulk of Funding From Stent Makers

2011-05-16T19:39:00.000+02:00

by Charles Ornstein
ProPublica, May 13, 2011, 1:27 p.m

Link

Many US medical associations and disease awareness groups depend heavily on funding by drug manufacturers

2011-05-16T19:36:00.000+02:00

BMJ 2011; 342:d2929 doi: 10.1136/bmj.d2929 (Published 10 May 2011)
Cite this as: BMJ 2011; 342:d2929

News

Many US medical associations and disease awareness groups depend heavily on funding by drug manufacturers

Jeanne Lenzer

+ Author Affiliations

1New York

Many medical societies and non-profit disease awareness organisations in the United States receive much of their funding from drug and device manufacturers, show documents recently released to the US senator Charles Grassley.

Senator Grassley, a Republican of Iowa, asked for financial information in December 2009 from 33 professional associations and groups that conduct research or promote disease awareness.

Among the organisations responding to Senator Grassley’s request was the American Medical Association, which reported that 16 drug, device, and communications companies donated nearly $5m (£3.1m; €3.5m) in 2007 for “continuing medical education” programmes and “communications conferences.”

Large donations to the association included $499 000 from Takeda Pharmaceutical Company, which makes the blockbuster antidiabetes drug pioglitazone, to conduct a continuing medical education programme on diabetes. Teva Neuroscience, maker of rasagiline, a treatment for Parkinson’s disease, gave $450 000 for a programme on Parkinson’s disease; and Purdue Pharma, maker of OxyContin, a formulation of the painkiller oxycodone, donated $212 000 for a programme on pain management.

The online investigative news organisation ProPublica (www.propublica.org), which scrutinised the documents received by Senator Grassley, says that manufacturers provided more than half of the total funding of the North American Spine Society in 2009, nearly half the funding of the Heart Rhythm Society in 2010, and more than 40% of the funding of the American Academy of Allergy, Asthma and Immunology in 2008.

Many organisations issue professional recommendations and guidelines on drugs and devices manufactured by the companies that fund the organisation. For example, the Heart Rhythm Society issues guidelines on drugs, catheters, pacemakers, and implantable defibrillators used for rhythm disturbances. A ProPublica report says that the device manufacturers Medtronic, Boston Scientific, and St Jude Medical gave the society $4m in 2010. Twelve of the society’s 18 directors also received undisclosed amounts of funding from the companies.

Senator Grassley told ProPublica, “If a group gets millions [of dollars] from a company that makes a product [prescribed] by its members, it is reasonable to wonder whether the guidance it offers on treatments would benefit that company.”

ProPublica reported that Bruce Wilkoff, the incoming president of the Heart Rhythm Society, said, “We either get out of the business or we manage these relationships. That’s what we’ve chosen to do.”

Jerome Hoffman, professor of emergency medicine at the University of Southern California in Los Angeles and an expert on industry influence in medicine, told the BMJ, “It’s unclear just what ‘business’ [Dr Wilkoff] is referring to, but the business of finding non-conflicted experts to write evidence based guidelines that serve the public in no way requires taking industry largesse.

“The very notion of ‘managing’ such relationships is . . . self serving. We need to ask what purpose medical societies should serve, and if the answer has anything to do with promoting the public health we should insist that they stop, consciously or otherwise, serving a very separate master.”

The American Medical Association did not respond to an inquiry by the BMJ regarding the reports.
Notes

Cite this as: BMJ 2011;342:d2929

Interessenkonflikte bei Erstellern amerikanischer kardiologischer Leitlinien

2011-04-30T20:31:00.002+02:00

Mendelson TB, Meltzer M, Campbell EG, Caplan AL, Kirkpatrick JN.
Conflicts of Interest in Cardiovascular Clinical Practice Guidelines.
Arch Intern Med 2011;171(6):577-84. (28.3.2011)
Abstract

Beitrag im Forum Gesundheitspolitik: Amerikanische kardiologische Leitlinien: kann man ihnen vertrauen? Link

Lücken in der Transparenz: Meta-Analysen zumeist ohne Angaben von Interessenkonflikten

2011-04-03T18:03:00.002+02:00

Roseman M, Milette K, Bero LA, Coyne JC, Lexchin J, Turner EH, et al. Reporting of Conflicts of Interest in Meta-analyses of Trials of Pharmacological Treatments. JAMA: The Journal of the American Medical Association 2011;305(10):10
Abstract

Lücken in der Transparenz: Meta-Analysen zumeist ohne Angaben von Interessenkonflikten
Beitrag im Forum Gesundheitspolitik Link

Knowledge of ghostwriting and financial conflicts-of-interest reduces the perceived credibility of biomedical research

2011-02-17T22:15:00.005+01:00

Die Offenlegung von Interessenkonflikten ist nicht nur theoretisch wichtig, sondern hat praktische Komsequenzen für die Verschreibungspraxis, denn sie trägt zur Skepsis bei. Das zeigt dieser kleine Versuch von Lacasse und Leo. Eine Schlussfolgerung der Autoren: "For industry [...] our results suggest that decreased disclosures are preferable" ist dann wohl auch eher als Warnung zu verstehen.

While the impact of conflicts-of-interest (COI) is of increasing concern in academic medicine, there is little research on the reaction of practicing clinicians to the disclosure of such conflicts. We developed two research vignettes presenting a fictional antidepressant medication study, one in which the principal investigator had no COI and another in which there were multiple COI disclosed. We confirmed the face validity of the COI vignette through consultation with experts. Hospital-based clinicians were randomly assigned to read one of these two vignettes and then administered a credibility scale.

Jeffrey R Lacasse, Jonathan Leo
Knowledge of ghostwriting and financial conflicts-of-interest reduces the perceived credibility of biomedical research
BMC Research Notes 2011, 4:27
www.biomedcentral.com/1756-0500/4/27

The Inverse Benefit Law: How Drug Marketing Undermines Patient Safety and Public Health

2011-02-17T22:01:00.006+01:00

Der Artikel, dessen Schwerpunkt die Ursachen irrationaler Verschreibung ist, weist besonders auf die Rolle von Interessenkonflikten bei der Erstellung von Leitlinien und deren Folgen hin.

Recent highly publicized withdrawals of drugs from the market because of safety concerns raise the question of whether these events are random failures or part of a recurring pattern.
The inverse benefit law, inspired by Hart’s inverse care law, states that the ratio of benefits to harms among patients taking new drugs tends to vary inversely with how extensively the drugs are marketed. The law is manifested through 6 basic marketing strategies: reducing thresholds for diagnosing disease, relying on surrogate endpoints, exaggerating safety claims, exaggerating efficacy claims, creating new diseases, and encouraging unapproved uses.

Howard Brody, MD, PhD, and Donald W. Light, PhD
The Inverse Benefit Law: How Drug Marketing Undermines Patient Safety and Public Health
Am J Public Health 2011
http://ajph.aphapublications.org/cgi/content/abstract/101/3/399

"Interessenkonflikte sind etwas ganz Natürliches"

2011-01-14T08:10:00.000+01:00

Medizinprofessor fordert Professoren auf, ihre Nebeneinkünfte zu offenbaren
Deutschlandfunk 13.1.2011
Website
Audio on demand

Gläserner Professor

2011-01-14T08:08:00.000+01:00

Spiegel online 3.1.2011 Link

Government oversight agency calls on NIH to ban ghost-writing

2010-12-03T18:26:00.002+01:00

Das US-Project on Government Oversight hat die National Institutes of Health (NIH) aufgefordert, Forscher, die Artikel von anderen Ghostwriten lassen, von der Förderung auszuschließen. Die Forderung wird mit mehreren Beispielen unterlegt.

Der einfachste Zugang und eine Reihe von interessanten Links in dem Blog von Alison Bass:

"Much has been written about the insidious practice of ghost-writing in medical research in this and other blogs and news articles. Even Dr. Francis Collins, the director of the National Institutes of Health (NIH), expressed dismay over the problem in a C-SPAN interview last year, calling it a threat to the "integrity of science." So far, however, not much has been done to curb such abuses"

Die öffentliche Reputation der Pharmaindustrie in den USA im Jahr 2009

2010-11-09T12:37:00.000+01:00

Annual RQ. 2009. Summary Report. A survey of the U.S. General pubic using the reputation quotient
Link

Beitrag im Forum Gesundheitspolitik

Physician Professionalism

2010-11-09T12:06:00.000+01:00

and Changes in Physician-Industry Relationships From 2004 to 2009. Arch Intern Med 2010;170(20):1820-26.
Campbell EG, Rao SR, DesRoches CM, Iezzoni LI, Vogeli C, Bolcic-Jankovic D, et al.
Abstract

Information from Pharmaceutical Companies

2010-11-07T22:38:00.001+01:00

and the Quality, Quantity, and Cost of Physicians' Prescribing: A Systematic Review.
PLoS Medicine 19.10.2010 Link

Richard Smith on editors’ conflicts of interest

2010-11-02T13:46:00.005+01:00

Der frühere Herausgeber des British Medical Journal schreibt in seinem Blog über Interessenkonflikte von Herausgebern. Link

Anlass ist der Beitrag im PLoS "Conflicts of Interest at Medical Journals". Link

Conflicts of Interest at Medical Journals: The Influence of Industry-Supported Randomised Trials on Journal Impact Factors and Revenue – Cohort Study

2010-10-27T23:35:00.003+02:00

Conclusions

Publication of industry-supported trials was associated with an increase in journal impact factors. Sales of reprints may provide a substantial income. We suggest that journals disclose financial information in the same way that they require them from their authors, so that readers can assess the potential effect of different types of papers on journals' revenue and impact.

Link

Meldung in aerzteblatt online 27.10.2010

Beitrag im Forum Gesundheitspolitik

Modeling in pharmacoeconomic studies: Funding sources and outcomes

2010-10-20T09:19:00.000+02:00

International Journal of Technology Assessment in Health Care 2010), 26: 330-333

Abstract

Conclusions:
The review found a substantial share of studies supported by the pharmaceutical industry, almost all concluding in favor of the drug studied, without any unfavorable conclusions at all. These results confirm also in the field of pharmacoeconomic studies that the best way of limiting confounding factors is by clearly distinguishing assessors from manufacturers and marketers of any new technology.

Industry sponsored bias in cost effectiveness analyses

2010-10-20T09:16:00.001+02:00

Editorial BMJ 19.10.2010

European Medicines Agency tightens rules on conflict of interest

2010-10-20T09:14:00.001+02:00

BMJ 19.10.2010

Publikationsbias - das Beispiel Reboxetin.

2010-10-15T22:15:00.004+02:00

Eyding D, Lelgemann M, Grouven U, Härter M, Kromp M, Kaiser T, et al.
Reboxetine for acute treatment of major depression: systematic review and meta-analysis of published and unpublished placebo and selective serotonin reuptake inhibitor controlled trials. Volltext kostenlos

Editorial der Herausgeberinnen des BMJ

Kommentar R. Steinbrook, JP Kassirer (frühere Herausgeber des New England Journal of Medicine)

Kommentar G. Gigerenzer

Beitrag im Forum Gesundheitspolitik

The Haunting of Medical Journals: How Ghostwriting Sold “HRT”

2010-09-29T14:22:00.001+02:00

The Haunting of Medical Journals: How Ghostwriting Sold “HRT”
Adriane J. Fugh-Berman. PLoS Medicine. September 7, 2010

Adriane Fugh-Berman examines documents unsealed in recent litigation to investigate how pharmaceutical companies promoted hormone therapy drugs, including the use of medical writing companies to produce ghostwritten manuscripts and place them into medical journals.

Download

SIEGEL-ONLINE: Pharmalobby diktiert Gesetzesänderung Nr. 4

2010-09-27T12:29:00.001+02:00

von Markus Grill
27. September 2010, 11:34 Uhr
Link

Diabetesmittel Rosiglitazon: EMA hebt Zulassung auf

2010-09-26T19:11:00.005+02:00

Beitrag in Gute Pillen - schlechte Pillen
Beitrag in Forum Gesundheitspolitik
Beitrag in Buko Pharma-Brief 4-5/2010: Gar nicht rosig - ein Diabetesmittel, das es nicht geben dürfte

Offenlegung von Interessenkonflikten: gravierende Lücken bei hohen Beträgen

2010-09-18T12:54:00.001+02:00

From Disclosure to Transparency: The Use of Company Payment Data.
Archives of Internal Medicine, 13.9.2010
Volltext kostenlos

Beitrag im Forum Gesundheitspolitik

Studienregister - kein Schutz vor manipulierten Studien

2010-09-18T12:51:00.003+02:00

Outcome Reporting Among Drug Trials Registered in ClinicalTrials.gov.
Annals of Internal Medicine 153(3): 158-166. 3.8.2010
Abstract

Beitrag dazu im Forum Gesundheitspolitik

Studienregister - kein Schutz vor manipulierten Studien

2010-08-30T15:18:00.001+02:00

Beitrag im Forum Gesundheitspolitik über die Studie: Outcome Reporting Among Drug Trials Registered in ClinicalTrials.gov." Annals of Internal Medicine 153(3): 158-166. Abstract der Studie

Patient & Consumer Organisations at the European Medicines Agency Financial disclosure and transparency.

2010-08-12T22:51:00.002+02:00

HAI Europe survey reveals new data on financial transparency of patient and consumer organisations
Two-thirds of the patient and consumer organisations working with the European Medicines Agency (EMA) received partial or significant funding from pharmaceutical manufacturers and/or industry associations, which suggests that the pharmaceutical industry is the prevalent sponsor of the patient voice at the EMA.

Fewer than half of the 23 organisations complied with EMA financial reporting guidelines. The EMA appears to have failed in the monitoring and enforcement its guidelines on financial transparency.

These and other main findings are reported in HAI Europe’s recent survey on levels of financial disclosure and transparency among patient and consumer organisations at the European Medicines Agency (EMA).

Read the Research Article and Factsheet on our website www.haieurope.org

Avandia panel member may be investigated for possible conflicts of interest.

2010-08-08T23:07:00.002+02:00

The US Food and Drug Administration has asked its parent department to investigate possible conflicts of interest relating to one of the members of the panel that recently recommended further restrictions on the drug rosiglitazone (marketed as Avandia), manufactured by GlaxoSmithKline (GSK) and used to control type 2 diabetes (BMJ 2010;341:c3862, 16 Jul, doi:10.1136/bmj.c3862). http://www.bmj.com/cgi/content/extract/341/aug03_2/c4083

Interessenkonflikte von Patientenvertretern bei der EMA

2010-07-16T14:52:00.004+02:00

In einem offenen Brief protestierte die International Society of Drug Bulletins (ISDB) gegen den laxen Umgang mit Interessenkonflikten bei der Europäischen Arzneimittelbehörde EMA. Zwei Patientenvertreter im Management Board der EMA hatten nicht angegeben, dass ihre Organisationen zu großen Teilen von der Pharmaindustrie finanziert werden. Nach Ansicht von ISDB liegt das Problem aber tiefer: "We call upon you to encourage the EMA to address this problem effectively. Consumer and patient organisations that are independent of any pharmaceutical or medical device industry support are better equipped to represent the interest of civil society." Aufgedeckt hatte die Verstrickung das Corporate Europe Observatory, link zum Bericht.

Disclosing Industry Relationships — Toward an Improved Federal Research Policy

2010-07-15T23:15:00.001+02:00

E.G. Campbell and D.E. Zinner. New England Journal of Medicine. 14.7.2010 Volltext Download

Diabetesmittel Avandia: unerwünschte Effekte in Studien unterdrückt

2010-07-12T10:11:00.007+02:00

Morgen und übermorgen (13./14.7.2010) tagt ein Expertengremium der FDA, um darüber zu beraten, ob das Diabetesmedikament Avandia (Rosigltazon) vom Markt genommen werden soll.
In einem 765-seitigen Bericht der FDA, in der die RECORD-Studie analysiert wird, werden 11 Fälle benannt, in denen unerwünschte Effekte des Arzneimittels nicht als solche gezählt wurden.

Caustic Government Report Deals Blow to Diabetes Drug. New York Times 10.7.2010

Kommentar Anton Safer: Dieses Beispiel zeigt wieder, dass zumindest die Aufsicht und Kontrolle ueber Studien in neutrale Haende gehoeren, die nicht vom Sponsor beeinflusst werden koennen. Ausserdem zeigt das Beispiel, wie wichtig die Offenlegung aller Detaildaten ist, um Betrug und Irrtuemer aufzudecken.

Testimony Encouraging Greater FDA Transparency

2010-06-28T10:30:00.003+02:00

Testimony of Peter Lurie, M.D., M.P.H., and Hillary Peabody, M.P.H., Health Research Group at Public Citizen Before the FDA Transparency Task Force 24 June 2010

Interessanter Beitrag der bekannten US-Verbraucherschutzgruppe zur FDA Anhörung zu Transparenz.

Volltext: http://www.citizen.org/Page.aspx?pid=573

Physician Attitudes Toward Industry: A View Across the Specialties

2010-06-24T00:15:00.000+02:00

Archives of Surgery 6. Juni 2010 Volltext kostenlos

From Evidence-based Medicine to Marketing-based Medicine: Evidence from Internal Industry Documents

2010-06-22T11:18:00.002+02:00

von Glen I. Spielmans & Peter I. Parry
Bioethical Inquiry
DOI 10.1007/s11673-010-9208-8
Received: 2 October 2009 / Accepted: 15 December 2009

Download zum Artikel: http://www.springerlink.com/content/b674622731k4850q/fulltext.pdf

Abstract: While much excitement has been generated surrounding evidence-based medicine, internal documents from the pharmaceutical industry suggest that the
publicly available evidence base may not accurately represent the underlying data regarding its products. The industry and its associated medical communication firms state that publications in the medical literature primarily serve marketing interests. Suppression and spinning of negative data and ghostwriting have emerged as tools to help manage medical journal publications to best suit product sales, while disease mongering and market segmentation of physicians are also used to efficiently maximize profits. We propose that while evidence-based medicine is a noble ideal, marketing-based medicine is the current reality.

Schöne neue Pharmawelt - Arzneimittelwerbung und Desinformation in Nord und Süd

2010-06-19T16:28:00.002+02:00

Pharma-Brief spezial 1/2010
Download als PDF
Bestellung im Online-Shop

JAMA 9.6.2010 Payments to Physicians, Medical Schools to Be Illuminated Under New Reform Law

2010-06-15T13:11:00.002+02:00

Extract

Website der Pew Foundation zum Physician Payments Sunshine Act

Archiv interner Dokumente der pharmazeutischen Industrie

2010-06-06T14:17:00.002+02:00

University of California, San Francisco: Drug Industry Document Archive
The Drug Industry Document Archive (DIDA) contains thousands of documents and resources about pharmaceutical industry clinical trials, publication of study results, pricing, marketing, relations with physicians and involvement in continuing medical education.

Most of these previously secret internal documents were made public as a result of lawsuits against a number of pharmaceutical companies including: Merck & Co., Parke-Davis, Warner-Lambert, Wyeth, and Pfizer. For further information on documents connected to these lawsuits, please consult The Documents.

Eine Befragung niedergelassener Fachärzte zum Umgang mit Pharmavertretern

2010-06-06T14:04:00.003+02:00

Studie von Klaus Lieb und Simone Brandtönies im Deutschen Ärzteblatt vom 4.6.2010.
Dazu im Forum Gesundheitspolitik: "Ärzte und Pharmavertreter - eine verhängnisvolle Affäre"

2010-05-31T22:21:00.005+02:00

13.4.2010 Trials: Reporting bias in medical research - a narrative review
Natalie McGauran*, Beate Wieseler, Julia Kreis, Yvonne-Beatrice Schüler, Heike Kölsch and Thomas Kaiser. Trials 2010, 11:37 doi:10.1186/1745-6215-11-37 Kostenloser Volltext

Eine lesenswerte Übersichtsarbeit vom IQWiG.

When Patients Meet Online, Are There Side Effects?

2010-05-31T10:30:00.002+02:00

Die New York Times berichtet in ihrer Ausgabe vom 28. Mai 2010 über die sich ausbreitenden "sozialen" Online-Patientennetzwerke:
http://www.nytimes.com/2010/05/30/business/30stream.html?th&emc=th

Diese Patientenportale wie CureTogether.com oder PatientsLikeMe.com bieten - teilweise moderiert - die Chance, dass sich Patienten gezielt vernetzen, z.B. auch mit "Leidensgefährten/innen".

Nebenwirkung von Therapien
Potentiell bieten diese Netze auch die Chance, schwere Nebenwirkungen von Therapien/Arzneimitteln sehr früh nach einer Markteinführung zu entdecken. Das wäre ja positiv im Sinne des Konsumentenschutzes - wenn es denn angemessen umgesetzt wird!
Auch Arzneimittelzulassungbehörden hätten hier die Chance auf einen frühen Erkenntnisgewinn - zB eine Hersteller-unabhängige Post-marketing Surveillance.
Noch ist es dafür aber zu früh, denn die Systeme sind noch bei zu wenigen Personen im Gebrauch, und sie sind für solche Zwecke weder konzipiert, noch habe ich cen Eindruck, dass sie ausgereift sind.
Es ist also noch keinesfalls klar, ob und wie dieses Potential genutzt werden wird und kann.

Patienten-Portale sind ein Quell zahlreicher Interessenskonflikte
Da sind zunächst die Portalbetreiber, die die Daten der Nutzer kommerziell verwerten können, und zwar für Werbezwecke, für das Verkaufen an Pharma- oder Heilmittelhersteller an Krankenversicherer, Krankenhausbetreiber, oder für die gezielte Vermarktung von Produkten im Auftrag Dritter.
Die Gefahr der verdeckten Manipulation von Patienten (und sicher auch Ärzten) ist enorm hoch und wird auch im Artikel diskutiert.
Dann sind da noch die Datenkäufer: es dürfte schwierig zu kontrollieren sein, was sie mit den Daten anstellen.
Die Patienten erklären mit dem Einverständnis zu den Nutzungsbedingungen, dass sie mit der Verwertung der von ihnen gespeicherten Daten einverstanden sind, und haben sich damit nach Amerikanischem Recht selbst fast aller Rechte beraubt. Ob sie wissen, was sie da tun? Sind sie sich der Folgen bewusst?
Die Moderatoren könnten (offenlegungspflicht über finanzielle Interessen gibt es nicht) ihre Rolle missbrauchen, zB. als versteckte Werbeagenten.
Auch Ärzte könnten solche Portale für ihre Zwecke nutzen, sich auch unter falscher Identität eintragen. Das könnte auch ein Mittel zur erlangung von Vorteilen im Konkurrenzkampf sein.

24.5.2010 JAMA Managing Financial Conflict of Interest in Biomedical Research.

2010-05-30T19:43:00.003+02:00

Rockey SJ, Collins FS. Managing Financial Conflict of Interest in Biomedical Research. JAMA 2010;303(23):jama.2010.774.
Volltext kostenlos.

Neuer Blog Interessenkonflikte

2010-04-22T18:35:00.002+02:00

Dieser Blog des Deutschen Netzwerks Evidenzbasierte Medizin soll über wichtige Veröffentlichungen zum Thema Integrität der Wissenschaft / Interessenkonflikte informieren.

Gespeist wird der Blog von einigen Personen, die fortlaufend Fachzeitschriften auf neue Veröffentlichungen screenen.

Es werden aber auch ausgewählte ältere Dokumente eingegeben. Hier z.B. eine Liste mit 11 Publikationen, die mir besonders wichtig erscheinen.

Die Veröffentlichungen werden kurz oder gar nicht kommentiert.

David Klemperer